Invivyd Inc. (IVVD) - Total Liabilities
Based on the latest financial reports, Invivyd Inc. (IVVD) has total liabilities worth $38.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Invivyd Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Invivyd Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Invivyd Inc. Competitors by Total Liabilities
The table below lists competitors of Invivyd Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lotte Data Communication Company
KO:286940
|
Korea | ₩470.23 Billion |
|
EASY HOLDINGS Co. Ltd
KQ:035810
|
Korea | ₩1.79 Trillion |
|
Security National Financial
NASDAQ:SNFCA
|
USA | $1.16 Trillion |
|
Premier Marketing Public Company Limited
BK:PM
|
Thailand | ฿1.48 Billion |
|
BlackRock Investment Quality Municipal Closed Fund
NYSE:BKN
|
USA | $140.98 Million |
|
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
USA | $54.05 Million |
|
Bell Equipment Limited
JSE:BEL
|
South Africa | ZAC3.30 Billion |
|
Sporting Clube de Portugal - Futebol SAD
LS:SCP
|
Portugal | €379.82 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Invivyd Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Invivyd Inc. asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Invivyd Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Invivyd Inc. (2020–2025)
The table below shows the annual total liabilities of Invivyd Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $35.34 Million | -42.97% |
| 2024-12-31 | $61.98 Million | +19.85% |
| 2023-12-31 | $51.71 Million | +90.14% |
| 2022-12-31 | $27.20 Million | -56.18% |
| 2021-12-31 | $62.07 Million | -66.01% |
| 2020-12-31 | $182.63 Million | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more